Skip to main content
. 2020 Oct 15;12(10):2991. doi: 10.3390/cancers12102991

Figure 3.

Figure 3

KIR+ NK cell repertoire in healthy controls and cancer patients. (A) Frequency of KIR+ NK cells in peripheral blood of healthy controls (n = 42) and cancer patients (80 melanomas, 80 bladder cancers and 89 ovarian cancers). (B) Frequency of KIR+ NK cell subsets in cancer patients according to the presence of the HLA C1- and C2-ligands, respectively. ** p < 0.01, comparing KIR2DL1+ NK cells in HLA-C2 positive (C1C2 or C2C2) and negative (C1C1) cancer patients. (C) Frequency of KIR2DL2/S2+ and KIR2DL1+ NK cells in all patients (n = 249), patients who survived.